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Abstract
Background: Canine B-cell lymphoma is deemed an ideal model of human non-Hodgkin’s lymphoma where the
lymphomas of both species share similar clinical features and biological behaviors. However there are some
differences between tumor features in both species. In the current study, we sought to evaluate the prognostic
efficacy of human B-cell lymphoma prognostic gene signatures in canine B-cell lymphoma.
Methods: The corresponding probe sets of 36 human B-cell lymphoma prognostic genes were retrieved from 2
canine B-cell lymphoma microarray datasets (GSE43664 and GSE39365) (76 samples), and prognostic probe sets
were thereafter detected using the univariate and multivariate Cox proportional-hazard model and the Kaplan–Meier
analysis. The two datasets were employed both as training sets and as external validation sets for each other. Results
were confirmed using quantitative real-time PCR (qRT-PCR) analysis.
Results: In the univariate analysis, CCND1, CCND2, PAX5, CR2, LMO2, HLA-DQA1, P53, CD38, MYC-N, MYBL1, and BIRCS5
were associated with longer disease-free survival (DFS), while CD44, PLAU, and FN1 were allied to shorter DFS. However,
the multivariate Cox proportional-hazard analysis confirmed CCND1 and BIRCS5 as prognostic genes for canine B-cell
lymphoma. qRT-PCR used for verification of results indicated that expression level of CCND1 was significantly higher
in B-cell lymphoma patients with the long DFS than ones with the short DFS, while expression level of BIRCS5 wasn’t
significantly different between two groups.
Conclusion: Our results confirmed CCND1 as important gene that can be used as a potential predictor in this
tumor type.
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Background
Lymphoma is one of the most common malignancies in
dogs and occurs in different forms, including multi-
centric, mediastinal (thymic), alimentary, cutaneous, and
solitary types [1, 2]. Investigators have proposed canine
B-cell lymphoma as a suitable model of human non-
Hodgkin lymphoma (NHL) because the tumors of both
species have common clinical manifestations and biological
properties. However there are some differences between
tumor features in both species [3, 4].
Some clinical and histological features have been pro-
posed as prognostic factors in canine lymphoma [2, 5, 6].
For example, there are conflicting data on the use of the
Kiel and Working Formulation classifications insofar as
studies have revealed that both classifications are unreli-
able prognosticators [2, 5]. Nonetheless, in a study by
Teske et al. (1994), the Working Formulation classification
and Kiel classification were suggested as prognostic factors
for the overall survival and time-to-relapse in treated dogs
with malignant lymphoma, respectively [7]. Moreover,
investigations have reported that such clinical parameters
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as age, sex, animal weight, and clinical stage have no ro-
bust efficiency for predicting overall survival and disease-
free survival (DFS) times [5]. Some cellular proliferation
markers such as Ki-67, PCNA, and AgNOR have been
evaluated as suitable prognosis predictor. Indeed, Ki-67
and AgNOR have been reported as appropriate prognostic
markers in human and canine malignant lymphoma
[5, 8, 9], where AgNOR can be utilized for the grading
of the canine and human NHL [10, 11].
Molecular phenotyping is a robust method for the
definition of tumor subtypes and the detection of
prognostic gene genes [12–15]. For instance, the gene ex-
pression profile analysis divided human diffuse large-B-
cell lymphoma (DLBCL) into 3 distinct subtypes: activated
germinal center-like B-cell lymphoma, B-cell lymphoma,
and peripheral mediastinal B-cell lymphoma [12]. A simi-
lar investigation classified canine malignant lymphoma
based on molecular profiling [6]. In different studies, 36
genes have been suggested as prognostic markers for
human B-cell lymphoma (majorly DLBCL) (Table 1). To
the best of our knowledge, there is limited information on
the prognostic efficacy of these important gene markers in
canine B-cell lymphoma as an ideal model of human
NHL. In the present study, the robustness of these genes
for the prediction of DFS in 2 canine B-cell lymphoma
microarray datasets was investigated using the univariate/
multivariate Cox proportional-hazard model and the
Kaplan–Meier analysis. The prognostic efficacy of selected
gene(s) in each dataset was validated via the other dataset.
Methods
Microarray expression datasets
Two canine B-cell lymphoma microarray datasets,
namely GSE43664 [16] and GSE39365 [6] (platform:
GPL3738), were obtained from the GEO database
(http://www.ncbi.nlm.nih.gov/geo/). Expression data were
downloaded in the CEL file format. The GSE43664 and
GSE39365 datasets comprised 58 and 36 samples,
respectively, where the GSE43664 samples were solely
canine B-cell lymphoma (mainly diffuse large B-cell
lymphoma [DLBCL]) and the GSE39365 samples con-
tained both B-cell (n = 18) and T-cell lymphoma (n = 18).
In the GSE39365 dataset, only B-cell lymphoma samples
were included in the study. B-cell lymphoma samples
in GSE43664 included DLBCL (mainly), MZL, and un-
known. Additionally, B-cell lymphoma samples in
GSE39365 included DLBCL (mainly), MZL, and BL.
The clinical features of the studied cases are summarized in
Additional file 1: Table S1 and S2. The data were first con-
verted into expression values and then transformed loga-
rithmically using the Affy package [17] in R environment,
version 3.0.2 (http://www.r-project.org/). Survival time,
compared using Student's t-test between two datasets
(GSE43664: 9.6 ± 8.7 months and GSE39365:11.7 ± 12.1
months), wasn’t statistically different (P = 0.42).
Extraction of prognostic gene expression values
Thirty-six human-specific genes, presumed as prognostic
genes, were tested in the current study (Table 1). The lite-
ratures were mined to retrieve papers exploring prognos-
tic genes or gene signatures in human B-cell lymphoma.
Public databases (especially PubMed) were screened for
papers describing genes predicting survival in human B-
cell lymphoma. Finally, 36 genes were extracted from pa-
pers, where some of these genes weren’t evaluated as a
single prognostic gene and proposed as a prognostic gene
signature with the other genes. So, to perform a com-
prehensive assessment, we included all genes in our
analysis. The corresponding probe sets of these genes
and the related expression value for each probe set
were retrieved from both datasets using MATLAB 7.8.0
(R2009a) (MathWorks, Natick, MA).
Survival analysis and external validation
Survival analysis was performed using Survival (http://
cran.r-project.org/package=survival) and Survcomp [18]
packages in R environment. The Cox proportional-
hazards analysis was used for constructing a model for
the prediction of survival. In this analysis, the associ-
ation between a group of covariates (genes) and the re-
sponse variable (DFS) was evaluated. Two datasets were
employed as training and validation (test) groups, where
important prognostic gene(s) was identified in a group
(training group) and then validated in the other dataset
Table 1 List of human B-cell lymphoma prognostic genes used
in our study
BCL2 [1–4] Ki-67 [5]
BCL6 [4, 6, 7] LMO2 [4, 8]
BCL7A [4] LRMP [4]
BIRC5 [9] MYBL1 [4]
CCND1 [10] MYCN [6]
CCND2 [8, 11] NPM3 [6]
CD10 [4] NR4A3 [12]
CD38 [4] P53 [13]
CD44 [14] PAX5 [15]
CFLAR [4] PDE4B [12]
CR2 [4] PIK3CG [4]
EEF1A1L4 [6] PLAU [6]
FN1 [6] PMS1 [4, 11]
HGAL [4, 6] PRDM1 [11]
HLA-DQA1 [6] SCYA3 [8, 11]
HLA-DRA [6] SLA [4]
ICAM1 (CD54) [16] SLAM [4]
IRF4 [4] WASPIP [4]
References were provided in Additional file 1
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(validation group). We used an external validation in-
stead of internal validation, as the former is generally
more robust to the overfitting problem [19].
First, the univariate Cox analysis was performed and
genes with a z score greater than 1.5 or less than -1.5
[13, 20] were selected for the multivariate Cox analysis,
where a negative score and a positive score associated
with longer and shorter survival respectivley. In the
multivariate Cox analysis, statistically significant genes
were entered into the analysis and significant covariate(s)
was detected at a P-value lower than 0.05. Survival curves
were depicted by Kaplan–Meier method and compared
using the log-rank test. Furthermore, some clinical prog-
nosis parameters such as animal age, sex, and tumor grade
(high or low) (Additional file 1: Table S2) were assessed in
the Cox analysis to determine their roles in the prediction
model.
Next, the external validation of the resulted prognostic
genes was determined. The prognostic gene(s) in each
group was tested in the other group via the Kaplan-
Meier method and the log-rank test. In addition, the
expression of the prognostic genes were compared in
human ABC-like (activated B-cell like) and human
GCB-like (germinal center B like) groups, because GCB-
like and ABC-like cases are associated with better and
poorer prognoses, correspondingly [21]. For this ana-
lysis, the patients were categorized as GCB-like and
ABC-like groups based on 1,180 canine-specific differen-
tially expressed probe sets proposed by Richards et al.
(2013) [16]. Grouping was carried out using the hierar-
chal clustering analysis provided in geWorkbench 2.5.1
package [22]. Subsequently, the expressions of the
prognostic genes were compared between the two
groups using the Student's t-test analysis provided in
geWorkbench 2.5.1 package.
Verification of the results by quantitative real-time PCR
(qRT-PCR)
qRT-PCR procedure was performed as previously de-
scribed [23, 24] on lymph node biopsy samples obtained
from 60 dogs with B-cell lymphoma. All applicable inter-
national, national, and/or institutional guidelines for the
care and use of animals were followed. Biopsy samples
were processed using hematoxylin and eosin (H&E)
staining method for the routine histopathology evaluation.
Samples were diagnosed and subtyped based on the
World Health Organization classification of hematopoietic
and lymphoid tissues [25]. CD79a and CD3 antibodies
(Dako, Denmark) were used for the confirmation of B-cell
phenotype. CD79a-positive and CD3-negative samples
were selected for subsequent analysis. Because mean
survival time of GEO datasets samples that had lower
expression (short survival) and higher expression (long
survival) values than CCND1 or BIRCS5 median value
were 6.9 months and 12.1 months respectively (see results),
the selected cases for qRT-PCR included 30 dogs with DFS
<7 months and 30 dogs with DFS >12 months. Mean age
of the dogs with DFS >12 months and dogs with DFS <7
months were 8.3 years (range: 3-12 years) and 7 years
(range: 2-10 years) respectively.
In brief, total RNA was extracted using Tripure isolation
reagent (Roche, Germany) according to the manufacturer's
protocol. cDNA was synthesized using Maxime RT PreMix
Kit (Intron biotechnology, Korea) according to the manu-
facturer's instructions. The cDNA synthesis reaction was
run at 45 °C for 60 min, followed by 95 °C for 5 min.
Synthesized cDNA was used for final PCR assay. SYBR
green-based quantitative real-time PCR (qRT-PCR) was
performed using the Applied Biosystems 7500 Real- Time
PCR system. Cycle conditions were 95 °C for 10 minutes,
followed by 40 cycles of 95 °C for 15 s, 52 °C for 45 s, and
72 °C for 1 min. Data were analyzed by SDS 2.0 software
(Applied Biosystems). Specific primers used for CCND1
and BIRCS5 were presented in Additional file 1: Table S3.
HPRT was used as the reference gene for normalization of
target gene expression. Comparative ΔCT-method was
used for calculation of relative expression of the target gene
[23]. Data are presented as fold change in gene expression
level of the target gene. Fold changes in gene expression
was compared between two groups (DFS <7 months vs.
DFS >12 months) by Student's t-test. A P value lower than
0.05 was considered significant.
Results
Probe sets corresponding to the prognostic genes were
obtained from both datasets and subjected to subse-
quent survival analysis. Ninety one probe sets corre-
sponding to 36 genes were retrieved from the each
datasets. In the univariate analysis, the genes with a z
score higher than 1.5 or lower than -1.5 were selected
for the multivariate analysis. The results of the univariate
analysis are summarized in Table 2. In the 58-sample
dataset, CCND1, CCND2, PAX5, CR2, BCL2L14, LMO2,
HLA-DQA1, P53, MYC-N, and BIRCS5 had z scores
lower than -1.5, which is associated with longer DFS.
Conversely, CD44, PLAU, and FN1 had positive z scores
(higher than 1.5), which is correlated with shorter DFS.
Moreover, in the 18-sample dataset, CCND1, BIRCS5,
MYC-N, LMO2, MYBL1, and CD38 had significant nega-
tive z scores (lower than -1.5). No genes with a z score
higher than 1.5 was detected in the univariate analysis of
the GSE39365 dataset (Table 2). Our subsequent multi-
variate analysis indicated that CCND1 was a robust
predictor in both datasets. Furthermore, BIRCS5 in the
GSE39365 dataset reached a statistically significant level
(Table 3).
Appropriate external validation was confirmed by vali-
dating the prognostic gene(s) in each group in the other
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group. The correlation between CCND1 and BIRCS5
expression and DFS time was tested using the Kaplan-
Meier estimator and log-rank test. The patients were
divided into high-risk and low-risk groups based on the
median of the CCND1 and BIRCS5 expression values,
and their survival durations were compared using the
log-rank test. High-risk and low-risk groups had expres-
sion values lower than and higher than the median value
Table 2 Univariate Cox proportional-hazard analysis of B-cell lymphoma prognostic gene signatures in GSE43664 and GSE39365
datasets
Coef Exp (coef) SE (coef) z score P
GSE43664 dataset
Cfa.21188.1.S1_s_at: (CCND2) -0.672 0.511 0.207 -3.24 0.0012
Cfa.19972.1.S1_at: (BCL2L14) -3.44 0.0321 1.26 -2.72 0.0065
CfaAffx.18137.1.S1_at: (CR2) -0.902 0.406 0.371 -2.43 0.015
CfaAffx.4397.1.S1_x_at: (PAX5) -1.03 0.357 0.446 -2.31 0.021
Cfa.37.1.S1_at: (BIRC5) -1.44 0.236 0.627 -2.3 0.021
Cfa.16248.1.S1_at: (CCND1) -0.505 0.604 0.257 -2.1 0.049
Cfa.16217.1.S1_s_at: (CR2) -0.527 0.59 0.272 -1.94 0.052
Cfa.182.1.S2_at: (HLA-DQA1) -0.467 0.627 0.241 -1.93 0.053
Cfa.10937.1.S1_at: (LMO2) -0.676 0.509 0.354 -1.91 0.056
CfaAffx.6511.1.S1_at: (MYCN) -1.19 0.304 0.63 -1.89 0.059
Cfa.15639.1.A1_at: (TP53) -0.373 0.688 0.202 -1.85 0.064
Cfa.5536.1.A1_at: (MYCN) -0.781 0.458 0.443 -1.76 0.078
CfaAffx.18218.1.S1_at: (CR2) -0.391 0.677 0.225 -1.74 0.083
CfaAffx.18149.1.S1_s_at: (CR2) -0.429 0.651 0.248 -1.73 0.083
CfaAffx.18202.1.S1_s_at: (CR2) -0.454 0.635 0.272 -1.67 0.095
Cfa.19191.1.S1_at: (PDE4B) -0.857 0.425 0.518 -1.65 0.098
CfaAffx.4400.1.S1_at: (PAX5) -1.65 0.192 1.05 -1.58 0.11
CfaAffx.11868.1.S1_at: (MYBL1) -1.21 0.297 0.773 -1.57 0.12
Cfa.3707.1.A1_s_at: (FN1) 0.622 1.86 0.415 1.5 0.13
Cfa.3800.2.S1_at: (CD44) 0.226 1.25 0.14 1.61 0.11
CfaAffx.11235.1.S1_s_at: (CD44) 0.259 1.3 0.142 1.82 0.068
Cfa.127.1.S1_s_at: (PLAU) 0.884 2.42 0.463 1.91 0.057
Cfa.3707.2.S1_at: (FN1) 0.277 1.32 0.129 2.15 0.031
CfaAffx.22155.1.S1_s_at: (FN1) 0.347 1.41 0.154 2.26 0.024
Cfa.3707.3.S1_s_at: (FN1) 0.827 2.29 0.336 2.46 0.014
GSE39365 dataset
Cfa.15826.1.S1_s_at: (BIRC5) -0.832 0.435 0.477 -1.74 0.081
Cfa.16248.1.S1_at: (CCND1) -0.923 0.397 0.54 -1.71 0.088
Cfa.5536.1.A1_at: (MYCN) -2.44 0.0875 1.44 -1.69 0.091
Cfa.10937.1.S1_at: (LMO2) -0.825 0.438 0.516 -1.6 0.11
Cfa.3619.1.S1_at: (CD38) -0.804 0.448 0.512 -1.57 0.12
Cfa.3619.1.S1_s_at: (CD38) -0.605 0.546 0.39 -1.55 0.12
CfaAffx.11868.1.S1_at: (MYBL1) -1.76 0.171 1.16 -1.52 0.12
Clinical features (GSE39365 dataset)
Age at diagnosis (years) 0.0774 1.08 0.0893 0.866 0.39
Sex 0.165 1.18 0.576 0.287 0.77
Grade -1.04 0.354 0.68 -1.53 0.13
Genes with z score higher than 1.5 or lower than -1.5 were listed. Exp (coef) indicates hazard ratio. Positive and negative z score denotes shorter and longer
survival time respectively
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respectively. The DFS time in the GSE43664 dataset was
statistically different in the survival curves constructed
based on CCND1 (P = 0.007) and BIRCS5 (P = 0.0042)
expressions (Fig. 1 b and c). However, the DFS time in
high-risk and low-risk groups of the GSE39365 dataset
tended to be significant (P = 0.058) (Fig. 2 b). Addition-
ally, the expression levels of CCND1 and BIRCS5 were
tested in the GCB-like and ABC-like groups. To that
end, the samples were first classified into two groups
based on 1,180 canine-specific probe sets. Then, the ex-
pression level of CCND1 was compared between the two
groups. For the GSE43664 dataset, a clear clustering pat-
tern was reconstructed (Additional file 1: Figure S1),
Table 3 Multivariate Cox proportional-hazard analysis of B-cell
lymphoma prognostic gene signatures in GSE43664 and
GSE39365 datasets
Coef Exp (coef) SE (coef) z score P
GSE43664 dataset
CCND1 -0.72 0.487 0.353 -2.041 0.041
GSE39365 dataset
BRICS5 -2.322 0.098 0.834 -2.785 0.0054
CCND1 -3.017 0.0489 1.427 -2.114 0.035
Exp (coef) indicates hazard ratio
Fig. 1 Survival analysis for evaluation of the correlation between GSE39365 prognostic genes and DFS time in GSE43664 dataset. Panel a indicated
Kaplan-Meier estimate with 95% confidence bound in GSE43664 dataset. There was significant correlation between DFS with CCND1 (b) (P = 0.007)
and BIRCS5 (c) (P = 0.042). Green and red lines indicated samples had higher and lower expression value than median value respectively
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while the GCB-like and ABC-like groups were not
clearly created for the GSE39365 dataset maybe because
of its small sample size (Additional file 1: Figure S2). Hence,
the T-test analysis was performed only on the GSE43664
dataset and reveled that the differences between CCND1
expression in the GCB-like (mean ± SD= 8.03 ± 0.86) and
ABC-like (mean ± SD = 7.7 ± 0.54) groups tended to be
significant (P = 0.052) while BIRCS5 expression in the
GCB-like (mean ± SD = 5.32 ± 0.21) and ABC-like (mean ±
SD= 5.26 ± 0.23) groups wasn’t significant (P = 0.36).
qRT-PCR analysis confirmed CCND1 as final prognos-
tic gene because CCND1 expression was significantly
higher in the dogs with DFS >12 months than the dogs
with DFS <7 months while expression level of the BIRCS5
wasn’t significantly different between two groups (Fig. 3).
As was expected in light of our literature review [2, 6],
clinical characteristics such as age, sex, and tumor grade
were not significant predictor components in canine B-
cell lymphoma. More statistical details about the pa-
tients' clinical characteristics are summarized in Table 2.
Discussion
Although prognostic gene genes for human NHL and
especially DLBCL have been meticulously investigated
by various researchers, there is little information on mo-
lecular prognostic genes for canine B-cell lymphoma.
For example, Rosenwald et al. (2002) [14] proposed
germinal-center B-cell, MHC class II, lymph-node, and
cell proliferation signatures as a molecular profiling for
predicting progression-free survival after chemotherapy
in patients with DLBCL. HLA-DPα, HLA-DQα, HLA-
DRα, and HLA-DRβ as members of the MHC class II
module; BCL-6 as a member of the germinal-center B-
cell module; fibronectin, α-Actinin, connective-tissue
growth factor, urokinase plasminogen activator, collagen
type IIIα1, and KIAA0233 as members of the lymph-
node module; and E21G3, c-myc, and NPM3 as mem-
bers of the proliferation module constituted the more
Fig. 2 Survival analysis for evaluation of the correlation between GSE43664 prognostic gene and DFS time in GSE39365 dataset. Panel a indicated
Kaplan-Meier estimate with 95% confidence bound in GSE39365 dataset. There correlation between DFS with CCND1 (b) tended to be significant
(P = 0.058). Green and red lines indicated samples had higher and lower expression value than median value respectively
Fig. 3 Quantitative real-time PCR (qRT-PCR) analysis of the prognostic
genes. Gene expression level of CCND1 was significantly higher in
patients with long DFS time (>12 months) than ones with short DFS
time (<7 months). No significant difference was detected in BIRCS5
expression level between two groups
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prominent elements of prognostic signatures [14]. Fur-
thermore, Lossos et al. (2004) [13] proposed a complex
of LMO2, FN1, BCL6, SCYA3, CCND2, and BCL2 as a
suitable predictor in patients with DLBCL, independent
of the International Prognostic Index (IPI). In addition,
the authors reported HGAL and BCL6 as predictors of
overall survival, independent of the IPI [26, 27]. A
comprehensive list of the prognostic genes in human
B-cell lymphoma and related studies is presented in
the Materials/Methods (Table 1).
The current study utilized human B-cell lymphoma
prognostic genes so as to detect valuable genes that can
serve as prognostic predictors in canine B-cell lymphoma.
There is currently no counterpart for the IPI as regards
canine lymphoma inasmuch as the prognostic efficacy of
the IPI is evaluated alongside molecular genes. Among
genes analyzed in our investigation, CCND1 was found to
be the most appropriate prognostic factor. CCND1 was
confirmed in both datasets while BIRCS5 was solely veri-
fied in one dataset. Additionally qRT-PCR verified CCND1
prognostic efficacy.
CCND1, encoding cyclin D1 protein, plays a critical
role in the cell cycle machinery; i.e. in G1-S transition.
The overexpression of CCND1 has been indicated in
various human B-cell lymphoma subtypes, including
mantle cell lymphoma (MCL) [28, 29], DLBCL [30–32],
and plasma cell myeloma [33]. Nevertheless, the overex-
pression of cyclin D1 is regarded as an unusual charac-
teristic in human DLBCL [34, 35]. In general, cyclin D1
has been proposed as the most critical prognostic gene
majorly in MCL [36, 37] and seldom for other human B-
cell lymphoma subtypes. In one study, cyclin D1 was
verified as an independent prognostic factor from the
IPI and 5-year overall survival was significantly higher in
cyclin D1-negative MCL than cyclin D1-positive MCL
(86% vs. 30%) [37]. Furthermore, the m-RNA level of
CCND1 in blood and bone marrow has been proposed
as an appropriate prognostic factor in patients with
MCL [38]. Cyclin D1 overexpression showed a correl-
ation with longer survival in breast carcinoma [39] and
colorectal cancer [40]. The results of our study demon-
strate that CCND1 is a favorable potential prognostic
predictor for canine B-cell lymphoma. The results of the
present study confirm that CCND1 is an important
potential prognostic gene in canine B-cell lymphoma
(especially DLBCL subtype) and should, accordingly, be
considered for further investigation in future studies.
There is no significant comparable data about prognostic
efficacy of the CCND1 in human DLBCL while studied
samples in our study were majorly DLBCL. In an study by
lossos et al [13], although univariate Cox proportional-
hazard analysis revealed that CCND1 was a genes with
negative z score (longer survival), CCND1 didn’t reach a
significant level for entering final multivariate analysis.
Additionally previous investigation revealed that patients
with cyclin-D1+ CD5+ DLBCL tended to be associated
with inferior survival, but the correlation was not statisti-
cally significant [32]. Discrepancy between prognostic effi-
cacy of the CCND1 in human (especially MCL) and
canine B-cell lymphoma can be described in some ways.
This discrepancy may stem from the use of different
methods for the analysis of CCND1 expression (e.g. imu-
nohistochemistry, Western blotting, or gene expression
analysis) [39, 40] or may related to the species-dependent
characteristics. Relationship between CCND1 expression
and survival time in human MCL was evaluated using
immunophenotyping methods [37], while we used a gene
expression profiling approach in our study. Additionally,
some obvious reverse findings have been found between
canine B-cell lymphoma and human counterpart. For ex-
ample, previous investigation indicated that in contrast to
human DLBCL, BCL6 and MUM1/IRF4 rarely expressed
in canine B-cell lymphoma [16]. Moreover, an inverse ex-
pression pattern for p65 and p52 were found in canine
and human DLBCL [41]. Furthermore, some potential
confounders such as microsatellite instability (MSI), the
CpG island methylator phenotype (CIMP), and BRAF mu-
tation have been suggested as another source of the incon-
sistent findings regarding association between CCND1
expression and clinical outcome [40]. These genetic aber-
rations haven’t been examined in canine B-cell lymphoma.
Another gene regarded as a prognostic factor in our
study was BIRCS5 (survivin), but it wasn’t confirmed in
final qRT-PCR assay. BIRCS5 is one of the most import-
ant inhibitors of apoptosis proteins (IAP) involved in the
inhibition of induced cell death in vitro and in vivo [42].
Previous investigations have revealed that overall survival
is significantly shorter in patients with high survivin ex-
pression in patients with MCL [43] and DLBCL [44]. Ana-
lysis has confirmed that survivin can play a role in the
prediction of survival independent of the IPI in DLBCL
cases [44, 45]. Be that as it may, some authors have indi-
cated that there is no correlation between survivin expres-
sion and survival or response to treatment in patients with
DLBCL [46]. The overexpression of survivin in other
cancers such as colorectal cancer and neuroblastoma is
associated with higher proliferation activity and higher
relapse rate [47, 48]. In our study, although BIRCS5 was
found to be a predictor of DFS in canine B-cell lymphoma
in multivariate Cox proportional-hazard analysis, this gene
wasn’t considered as suitable prognostic factor because its
expression level wasn’t significantly different between
patients with long or short survival time.
Conclusions
To the best of our knowledge, this has been one of the few
studies to explore prognostic genes in canine lymphoma
using gene expression data analysis. Although microarray
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data from human cancers are very extensive and inform-
ative, microarray data related to animal cancers are rare
and incomplete. When mining microarray databases such
as GEO and ArrayExpress, there are limited studies ex-
ploring canine cancers using gene expression profiling.
Similarly, there is same problem with the canine lympho-
ma. Our mining in the databases provided three datasets
(GSE43664, GSE39365, and GSE30881) with ideal sample
size on canine B-cell lymphoma, where clinical metadata
(including survival time) haven’t been provided for
GSE30881 dataset. Therefore, we excluded this dataset
and used other two datasets. However, to gain more
robust and reliable results, both datasets were used as
training and validation groups. Although our results
may affect by small sample size of a dataset, we hope
that with extending larger canine datasets, future studies
by our group or other veterinary oncology researchers will
provide more remarkable findings. In conclusion, although
the results of the present study reveal CCND1 as a poten-
tial prognostic factor in canine B-cell lymphoma, further
studies on more extensive gene expression databases are
required to clarify other prognostic genes which can be
used as robust survival predictors.
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